<DOC>
	<DOCNO>NCT02669030</DOCNO>
	<brief_summary>Depression ongoing insomnia common clinical presentation patient . Clinical data suggest patient insomnia receive concomitant treatment sleep aid experience robust antidepressant response along quicker response . The purpose clinical study compare effectiveness FDA-approved insomnia medication suvorexant , also know BelsomraÂ® , add-on treatment antidepressant placebo plus antidepressant treatment patient depression residual ongoing insomnia .</brief_summary>
	<brief_title>A Six Week , Randomized , Double-Blind Placebo-Controlled , Suvorexant Augmentation Study Antidepressant Treatment Major Depressive Disorder With Residual Insomnia</brief_title>
	<detailed_description>Many patient depression suffer residual insomnia . This study six week , randomize , double-blind , placebo-controlled , trial study suvorexant augmentation continue antidepressant therapy placebo continue antidepressant therapy . Patient volunteer must stable antidepressant treatment remain treatment duration study . Patient volunteer qualify enroll clinical trial either receive suvorexant 10 mg/day may adjust dose either 15 mg 20 mg/day . Treatment total six week addition clinical follow-up visit .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Provide write Informed Consent Diagnosis depression ( MDD ) Currently antidepressant Healthy and/or stable medically unwilling discontinue current use sedative hypnotics/sleep aids/benzodiazepines counter sleep aids/supplements currently use psychotropics antidepressant risk self harm suicide attempt within past 12 month history presence psychotic disorder know hypersensitivity suvorexant presence sleep disorder residual insomnia depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>